Page last updated: 2024-08-23

plicamycin and ER-Negative PR-Negative HER2-Negative Breast Cancer

plicamycin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, C; Liu, R; Yang, R; Zhang, H; Zhi, X; Zhou, Z; Zou, T	1

Other Studies

1 other study(ies) available for plicamycin and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1. Scientific reports, 2018, 01-18, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Plicamycin; Sp1 Transcription Factor; Transcription, Genetic; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2018

Article

Year

Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.

Scientific reports, 2018, 01-18, Volume: 8, Issue:1

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Plicamycin; Sp1 Transcription Factor; Transcription, Genetic; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018